AstraZeneca Reports meta-analysis Data for Crizanlizumab in Head and neck squamous cell carcinoma

AstraZeneca today announced meta-analysis results for Crizanlizumab in patients with Head and neck squamous cell carcinoma. The study demonstrated that Crizanlizumab achieves primary endpoint with statistical significance compared to standard of care or placebo. These results provide important insights into the treatment of Head and neck squamous cell carcinoma and support the continued development of Crizanlizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Crizanlizumab was consistent with previous observations, with no new safety signals identified.